Braidwell LP Sells 1,593,735 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Braidwell LP cut its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 51.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,477,102 shares of the company's stock after selling 1,593,735 shares during the quarter. Braidwell LP owned 2.16% of Replimune Group worth $17,888,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. bought a new position in Replimune Group during the fourth quarter valued at approximately $543,000. Swiss National Bank boosted its holdings in shares of Replimune Group by 57.4% in the 4th quarter. Swiss National Bank now owns 103,700 shares of the company's stock worth $1,256,000 after acquiring an additional 37,800 shares in the last quarter. Barclays PLC lifted its position in shares of Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after purchasing an additional 98,791 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Replimune Group by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company's stock worth $2,113,000 after purchasing an additional 11,893 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in shares of Replimune Group by 260.8% during the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock worth $523,000 after purchasing an additional 31,231 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Trading Down 0.8 %

Shares of Replimune Group stock traded down $0.06 during midday trading on Friday, reaching $7.71. The company had a trading volume of 1,352,895 shares, compared to its average volume of 899,337. The firm has a market cap of $593.79 million, a PE ratio of -2.51 and a beta of 0.68. The stock has a fifty day moving average price of $9.36 and a 200 day moving average price of $11.48. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, equities analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on REPL. HC Wainwright boosted their price objective on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, BMO Capital Markets lifted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Replimune Group currently has a consensus rating of "Buy" and a consensus price target of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.